FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and represents a method in vitro or ex vivo of producing induced smooth muscle cells (iSMC), characterized by positive expression of aSMA (actin-alpha smooth muscle), CD49a and CD146 and the fact that they are incompetent with respect to fusion. Method comprises the following steps: (a) recovering cells derived from skeletal muscle from skeletal muscle tissue obtained from a subject; (b) transdifferentiation of cells originating from skeletal muscles. Present invention also relates to an induced smooth muscle cell (embodiments), its use for screening drugs and in vitro or ex vivo use of cells derived from skeletal muscle for producing iSMC.
EFFECT: present invention provides cells which are safe and effective for use in smooth muscle tissue regeneration.
20 cl, 15 dwg, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR OBTAINING MUSCLE-DERIVED CELLS | 2018 |
|
RU2796929C2 |
| MESENCHYMAL STROMAL CELLS FOR TREATING SEPSIS | 2015 |
|
RU2715866C2 |
| USE OF ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS IN TREATING FISTULA | 2011 |
|
RU2608641C2 |
| APPLICATION OF STROMAL STEM CELLS OF FATTY TISSUE FOR FISTULA TREATMENT | 2006 |
|
RU2435846C2 |
| USE OF ADIPOSE-DERIVED STROMAL STEM CELLS FOR TREATING FISTULAS | 2016 |
|
RU2744977C2 |
| HUTC MODULATION OF PRO-INFLAMMATORY MEDIATORS OF LUNG AND PULMONARY DISEASES AND DISORDERS | 2013 |
|
RU2668389C2 |
| HUMAN UTERINE CERVICAL STEM CELL POPULATION AND USES THEREOF | 2014 |
|
RU2679500C2 |
| AMNIOTIC ADHESIVE CELLS | 2009 |
|
RU2562154C2 |
| METHOD FOR OBTAINING UNDIFFERENTIATED CELL | 1996 |
|
RU2215539C2 |
| ANTI-CANCER TARGETED IMMUNOTHERAPY WITH APPLICATION OF IL-12 | 2015 |
|
RU2689160C2 |
